Provided by Tiger Trade Technology Pte. Ltd.

Galectin Therapeutics

3.95
-0.0700-1.74%
Post-market: 3.950.00000.00%16:04 EDT
Volume:229.39K
Turnover:906.43K
Market Cap:398.95M
PE:-9.18
High:4.05
Open:4.02
Low:3.91
Close:4.02
52wk High:7.13
52wk Low:2.03
Shares:101.00M
Float Shares:48.17M
Volume Ratio:0.86
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4302
EPS(LYR):-0.4847
ROE:-3727.94%
ROA:-64.18%
PB:-2.87
PE(LYR):-8.15

Loading ...

Dec 31, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 19, 2025

Major Issues Report

Form 8-K - Current report
Dec 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 15, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 12, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 09, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 08, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 08, 2025

Major Issues Report

Form 8-K - Current report
Dec 03, 2025

Major Issues Report

Form 8-K - Current report
Nov 14, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 14, 2025

Major Issues Report

Form 8-K - Current report
Nov 13, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 10, 2025

Major Issues Report

Form 8-K - Current report
Sep 12, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 12, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 08, 2025

Major Issues Report

Form 8-K - Current report
Aug 14, 2025

Major Issues Report

Form 8-K - Current report
Aug 14, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]